Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NKTR 
Nektar Therapeutics (NKTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: NKTR (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $107.29
1 Year Target Price $107.29
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 131.95% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.11B USD | Price to earnings Ratio - | 1Y Target Price 107.29 |
Price to earnings Ratio - | 1Y Target Price 107.29 | ||
Volume (30-day avg) 8 | Beta 1.28 | 52 Weeks Range 6.45 - 66.92 | Updated Date 12/14/2025 |
52 Weeks Range 6.45 - 66.92 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -192.87% | Operating Margin (TTM) -267.45% |
Management Effectiveness
Return on Assets (TTM) -27.98% | Return on Equity (TTM) -180.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 934391918 | Price to Sales(TTM) 17.77 |
Enterprise Value 934391918 | Price to Sales(TTM) 17.77 | ||
Enterprise Value to Revenue 14.93 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 20341589 | Shares Floating 18909541 |
Shares Outstanding 20341589 | Shares Floating 18909541 | ||
Percent Insiders 0.66 | Percent Institutions 71.14 |
About Nektar Therapeutics
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.nektar.com |
Full time employees 61 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.